Theranos Care unit of Sarvodaya Hospital, Faridabad has become the first center in the Indian subcontinent to offer Terbium-161 therapy in India for patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic neuroendocrine tumors (NET) who have not responded to Lutetium-PSMA or PRRT Therapy.
Theranostics Centre in India a unit of Sarvodaya Hospital is also pioneering in Peptide Targeted Radionuclide Therapy (PTRT) with Terbium-161-FAP2286 for difficult to treat solid tumors like Soft Tissue Sarcoma, Colorectal cancer, Triple Negative Breast Cancer, Melanoma, Non-Small Cell Lung Cancer, Inoperable or metastatic Liver Cancer, Metastatic or recurrent Kidney Cancer, Ovarian cancer, Stomach Cancer etc.
This revolutionary treatment is available at only a handful of centers across Indian subcontinent & South-East Asia and marks a major leap forward in precision oncology.
What Is Terbium-161 Therapy?
Terbium-161 is a next-generation radiopharmaceutical that emits beta particles and Auger electrons, making it highly effective in targeting cancer cells—especially micrometastases that are often missed by conventional therapies.
- For mCRPC: Terbium-161 is used in PSMA-targeted therapy for patients who have progressed after Lutetium-177 PSMA treatment.
- For NETs: It is used in somatostatin receptor-targeted therapy for patients who have failed PRRT.
- For Solid Tumors: Who have progressed or failed to respond to first line of treatment
This dual emission profile allows for enhanced tumor cell killing while minimizing damage to surrounding healthy tissues.
Terbium Therapy Backed by Global Research
Terbium-161 is currently being evaluated in international clinical trials such as:
- VIOLET Trial: Investigating Tb-161 PSMA-617 in prostate cancer patients post-Lu-177 failure.
- FAP-2286 Studies: Exploring Tb-161 labeled FAPI compounds for NETs and other solid tumors.
Preclinical studies have shown that Tb-161 may outperform Lu-177 Therapy in treating small-volume disease, thanks to its Auger electron emission, which is particularly lethal to cancer cells at close range.
Why Theranostics Centre in Delhi NCR, India a unit of Sarvodaya Hospital?
Sarvodaya Hospital is the first theranostics center in India to offer Tb-161 therapy, led by a team of experts in nuclear medicine specialist and oncologist in India. Patients benefit from:
- Personalized treatment planning
- Advanced imaging and dosimetry
- Multidisciplinary care
- Compassionate counseling and follow-up
Dr. Swagat Dash, Head of Nuclear Medicine, notes:
“Terbium-161 therapy represents a paradigm shift in cancer care. We’re proud to bring this innovation to India and offer renewed hope to patients who had exhausted conventional options.”
Who Can Benefit Terbium-161 Therapy?
You may be eligible if you have:
- mCRPC with progression after Lu-177 PSMA therapy
- Metastatic NET with progression after PRRT Therapy
- Any difficult to treat solid tumors like Soft Tissue Sarcoma, Colorectal cancer, Triple Negative Breast Cancer, Melanoma, Non-Small Cell Lung Cancer, Inoperable or metastatic Liver Cancer, Metastatic or recurrent Kidney Cancer, Ovarian cancer, Stomach Cancer etc
- Adequate organ function and performance status
- No contraindications to radiopharmaceutical therapy
What to Expect in Terbium-161 Therapy?
- Procedure: Tb-161 is administered via IV injection in a day-care setting.
- Duration: Typically given in cycles (4-6 cycles usually), depending on disease and response (6-8 weeks gap between each cycle).
- Side Effects: Mild fatigue, nausea, or blood count changes—usually manageable.
- Recovery: Most patients resume normal activities within a day.
Join the Movement for Precision Oncology India
Help us spread awareness about this breakthrough therapy.
